Comparing Two Ways of Explaining Ketamine Treatment for Hard-to-Treat Depression
Compares two ways of explaining ketamine to adults with treatment-resistant depression.
Plain-language title generated from the registry record
Registry title: Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing
Key facts
- Where
- Skövde, SwedenSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have been prescribed ketamine treatment for depression. It compares two ways of explaining the ketamine treatment to patients.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Depression that is treated with prescribed ketamine (treatment-resistant depression).
- Earlier treatment
- Must have been prescribed ketamine treatment for depression.
Main reasons for not taking part
- People who have not been prescribed ketamine treatment for depression
- People who cannot understand the study information and give informed consent
Read by machine on 9 November 2026.
Where in Sweden
- Brain Stimulation Clinic, Skaraborg's HospitalSkövde, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Valdemar Landgren
- Trial code
- NCT07824973
- Record updated
- 17 September 2026
- Original description
Ketamine is a medicine used in psychiatry for treatment-resistant depression. This study compares two ways of framing ketamine treatment: a psychedelic framing and a biomedical framing. The study will examine whether the framing affects depressive symptoms, treatment experience, tolerability, and longer-term outcomes.Read full original descriptionShow less
A Single-center Open-label Randomized Parallel-group Superiority Trial to Compare the Efficacy of Psychedelic and Biomedical Framing of Intravenous Ketamine for Treatment-resistant Depression - the KetSet Trial
Ketamine is a medicine used in psychiatry for treatment-resistant depression. This study compares two ways of framing ketamine treatment: a psychedelic framing and a biomedical framing. The study will examine whether the framing affects depressive symptoms, treatment experience, tolerability, and longer-term outcomes.
Inclusion: Prescribed ketamine treatment for depression; Able to understand study information and provide informed consent.
Exclusion: Patients who do not meet the inclusion criteria.